Deep EigenMatics: AI-Driven Drug Discovery at Unprecedented Speed
Developing breakthrough therapeutics across Metabolic, Oncology, and Rare Disease — powered by the #1 global ranking in AI-drug discovery patent families for 2025. Targeting lead oral GLP-1 asset advancing to IND within 24 months.
Institutional Proof
Patent Leadership in AI Drug Discovery
The Benchmark That Matters
Deep EigenMatics has secured the #1 global ranking in AI-drug discovery methods patent families for 2025, establishing an intellectual property position that fundamentally restructures competitive dynamics in computational pharmaceutical development. The company holds 16 patent filings (5 granted, 11 pending) protecting foundational mathematical architectures.
The company's AI-drug discovery patent families granted in 2025 exceeded the entire Big Pharma sector by 2x and surpassed all major AI drug discovery competitors — including Google DeepMind (Isomorphic Labs), Insilico Medicine, and Recursion Pharmaceuticals.
Founded by Dr. Stephen G. Odaibo, trained in the Nobel Prize-winning Lefkowitz Lab (birthplace of GPCR science underlying GLP-1 biology), Deep EigenMatics combines world-class scientific foundations with unprecedented IP protection.
#1
Global AI-Drug Discovery Methods Patent Rank — 2025 patent leadership across all pharmaceutical entities
2x Big Pharma
AI Drug Discovery Methods Patent families granted in 2025 exceeded entire Big Pharma sector
Platform IP Moat
Foundational mathematical architectures, not individual compounds
Multi-Track Exit Optionality
Acquisition, partnership, or IPO pathways
Press & Recognition
Press & Recognition
Deep EigenMatics Ranks #1 Globally in AI Drug Discovery, Outpacing All of Big Pharma in 2025 Patent Output
February 3, 2026 - Source: PR Newswire
Deep EigenMatics, Inc., a pioneer in high-velocity Artificial Intelligence for drug design, announced today that it has secured the #1 global ranking for new U.S. patent families in AI Drug Discovery methods for 2025.
2025 U.S. Patent Count: AI Drug Discovery Innovation
This chart shows Deep EigenMatics' leading position in AI drug discovery patent families compared to all major competitors and Big Pharma in 2025.
The chart highlights Deep EigenMatics' superior patent output — leading all AI drug discovery companies and outpacing the entire Big Pharma sector, demonstrating a highly optimized and productive R&D model.
Lead Asset
Lead Asset: The Oral GLP-1 "Holy Grail"
The global GLP-1 receptor agonist market represents a $100B+ opportunity dominated by injectable formulations. Novo Nordisk's Rybelsus represents the only FDA-approved oral option since 2019, but its commercial trajectory has been constrained by fundamental pharmacokinetic limitations: less than 1% bioavailability requiring absorption enhancers and complex dosing protocols that limit patient adherence and market penetration.
DEEP DISCOVERY™ AI Platform
Deep EigenMatics is utilizing its proprietary DEEP DISCOVERY™ AI Platform—integrating patented conditional multi-headed neural networks, probabilistic reasoning architectures, recursive transformers for protein-protein interaction mapping, and conformational state targeting—to computationally engineer a next-generation oral GLP-1 candidate that addresses current pharmacokinetic limitations through AI-optimized generative drug design.
Comprehensive IP Fortress
The candidate will be protected by comprehensive IP coverage across process, manufacturing methods, composition of matter, and formulation strategy, creating a defensible fortress around what may become the first best-in-class oral GLP-1 to reach market.
Value Inflection
AI-Driven Economics: Redefining Drug Development
Deep EigenMatics leverages AI to fundamentally restructure the economics, timeline, and risk profile of pharmaceutical innovation compared to traditional empirical approaches.
Dramatically Reduced Capital Requirements
Computational design enables multi-program development at a fraction of traditional pharmaceutical investment.
Accelerated Development Timelines
In-silico validation compresses the path from discovery to IND-ready candidate by years compared to empirical methods.
De-Risked Clinical Progression
Pathway prediction and safety screening reduce clinical uncertainty before entering costly human trials.
Multi-Program Platform
Therapeutic-agnostic discovery architecture enables simultaneous advancement across Metabolic, Oncology, and Rare Disease programs.
Comprehensive IP Protection
Foundational mathematical architectures combined with composition and formulation patents create a defensible innovation fortress.
The transition from capital-intensive, empirical drug development to AI-driven computational design represents a categorical shift in how pharmaceutical value is created.
🔒 Detailed economic analysis, competitive benchmarking, and financial projections available under NDA.
Platform Architecture
Foundational Mathematics: The Engine
Deep EigenMatics' competitive advantage originates from a portfolio of granted and pending patents protecting mathematical innovations that fundamentally advance the state of computational drug discovery, creating an unparalleled infrastructure for AI-driven pharmaceutical innovation beyond current-generation architectures. Each capability below is protected by granted U.S. patents, creating enforceable legal barriers to competitive entry. Full patent numbers, claim charts, and freedom-to-operate analyses available under NDA.
Five Granted U.S. Patents Protecting Core Platform
Conditional Multi-Headed Neural Networks
Proprietary architecture for joint synthesis of amino acid sequences and structural parameters in a single synchronized process, enabling discovery of novel compositions with optimal target-binding affinity and enhanced drug-likeness.
Probabilistic Reasoning for Autoregressive Models
Methodology for diverse library generation that comprehensively explores chemical space to identify high-affinity candidates with superior drug-likeness constraints.
Recursive Transformers for Protein-Protein Interaction
Architecture for accurately mapping complex protein-protein interactions and simulating downstream signaling cascades, enabling in-silico safety screening and efficacy prediction.
Conformational State Targeting
Methodology to distinguish between conformational states and generate ligands that trigger therapeutically specific conformational changes, ensuring functional selectivity beyond mere binding affinity.
Dynamic Context Refresh Mechanisms
System that dynamically updates context during drug generation, ensuring molecules continuously adhere to drug-likeness constraints and evolve towards optimized properties.
Strategic IP Assets
The IP Fortress: 16 Patent Filings (5 Granted, 11 Pending)
Deep EigenMatics holds a portfolio of 16 patent filings (5 granted, 11 pending) constituting the foundational intellectual property architecture of the platform. The five granted patents below establish discrete and enforceable barriers to competitive entry in AI-driven drug discovery, with 11 additional patents pending to further expand the moat.
All five patents are 100% assigned to Deep EigenMatics, Inc. Full claim charts, prosecution histories, freedom-to-operate analyses, and commercial exploitation strategies available in the institutional Data Room upon NDA execution.
Scientific Leadership
Leadership Infrastructure: Execution Pedigree
Dr. Stephen G. Odaibo,
M.D., M.S. (Math), M.S. (Comp. Sci.)
Founder & CEO
Founder & CEO
- Trained in Nobel Prize-winning Lefkowitz Lab (Duke University)
- Birthplace of GPCR science and foundational biology of GLP-1 receptors
- 2012 Nobel Prize in Chemistry for GPCR research
- Architect of the IP fortress and inventor of foundational platform technologies
- Published in Nature and leading scientific journals
- Author: The Foundational Mathematics of Artificial Intelligence
- Dual expertise: Deep mathematical foundations + clinical drug development insight
Leadership Team
Complemented by deep expertise in data infrastructure, IP strategy, and computational scaling. The team includes proven technology entrepreneurs with successful exits and pioneering IP development experience, leading defensive roadmap execution to protect the #1 global patent position.
World-Class Advisory & Operational Infrastructure: Deep EigenMatics has secured commitments from top-tier scientific and regulatory advisors with extensive pharmaceutical R&D experience. Full advisory board composition and institutional partnerships available under NDA.
Market Context
The GLP-1 Market: Scale, Trajectory, and the Oral Opportunity
A Market Structurally Awaiting Oral Delivery
The global GLP-1 receptor agonist market is among the fastest-expanding therapeutic categories in modern pharmaceutical history. Current injectable market leaders — semaglutide, tirzepatide — have demonstrated transformative clinical efficacy, yet their delivery modality imposes a structural ceiling on patient penetration.
Conservative epidemiological modeling indicates that needle-aversion and administration burden exclude an estimated 40–60% of the clinically eligible obesity and type 2 diabetes population from sustained GLP-1 therapy. Oral delivery dissolves this ceiling entirely.
Deep EigenMatics is positioned as the only patent-protected, AI-native platform with a computationally validated oral GLP-1 candidate program — at the precise moment when institutional capital is seeking exactly this exposure.
Investment Opportunity
Raising Seed Capital to Achieve IND-Ready Status
Deep EigenMatics is raising seed capital to achieve IND-ready status on its lead oral GLP-1 asset on an accelerated timeline, while simultaneously expanding the discovery platform to generate additional patent-protected assets across multiple therapeutic verticals.
Capital Deployment Strategy
Lead Asset Advancement
Digital candidate lock, in-vitro validation, in-vivo studies, and IND-enabling studies
Platform Expansion
Metabolic, Oncology, and Rare Disease programs across multiple therapeutic verticals
IP Generation
Continued IP generation and defensive patent portfolio expansion
Team & Infrastructure
World-class team expansion and advisory infrastructure
Value Creation Milestones
01
Computational Candidate Lock
AI-validated lead oral GLP-1 candidate confirmed with full platform data package
02
Experimental Validation
In-vitro and in-vivo data confirming efficacy and safety profile of lead asset
03
IND-Ready Status
Full IND submission readiness achieved, enabling Phase I initiation
Detailed capital allocation, milestone-based valuations, and financial projections available under NDA.
The phased deployment strategy creates clear value inflection points at each milestone, positioning Deep EigenMatics for multi-track strategic optionality within 36 months: acquisition by pharmaceutical entities seeking AI infrastructure, strategic partnership with Big Pharma for platform access, or IPO as a category-defining AI-pharma company.
Strategic Positioning
Infrastructure-Layer Value: Request NDA Access
Deep EigenMatics represents a category-defining opportunity at the intersection of AI and pharmaceutical development. The combination of foundational IP, capital-efficient execution, and multi-program platform architecture creates unprecedented strategic optionality.
Why This Matters
The infrastructure-layer patent portfolio ensures valuation resilience across all exit scenarios. Any institution seeking to compete in AI-accelerated drug development must either:
License Deep EigenMatics' Foundational IP
The fastest and most capital-efficient path to AI-driven drug discovery
Multi-Decade Alternative Development
Capital-intensive efforts to develop alternative mathematical frameworks — a barrier that increases exponentially with each additional patent filing
This is an existential barrier to entry that compounds over time, protecting institutional investor returns across every strategic exit pathway.
Access the Full Data Room
The following are available to qualified investors under NDA:
Technical Specifications
Detailed technical documentation and complete patent portfolio analysis
Financial Models
Granular financial models and milestone-based valuation framework
Leadership & Commitments
Advisory board composition and institutional partnership commitments
The strategic implication is unambiguous: this is not a single-asset biotech bet. This is infrastructure-layer positioning in the next generation of pharmaceutical discovery.